HER2-positive esophageal adenocarcinoma

HER2-positive esophageal adenocarcinoma is a distinct molecular subtype of esophageal malignancy affecting the glandular mucosa, predominantly of the lower third of the esophagus and the gastroesophageal junction It is pathologically characterized by the overproduction of human epidermal growth factor receptor 2 protein, gene amplification of *ERBB2*, or both, typically evaluated via immunohistochemistry and in situ hybridization assays

HER2-positive esophageal adenocarcinoma is a distinct molecular subtype of esophageal malignancy affecting the glandular mucosa, predominantly of the lower third of the esophagus and the gastroesophageal junction

It is pathologically characterized by the overproduction of human epidermal growth factor receptor 2 protein, gene amplification of *ERBB2*, or both, typically evaluated via immunohistochemistry and in situ hybridization assays This aberrant receptor overexpression drives unrestrained cellular proliferation, tumor growth, and resistance to apoptosis, typically defining a biologically aggressive cancer subset that is selectively eligible for HER2-targeted oncologic therapies

This aberrant receptor overexpression drives unrestrained cellular proliferation, tumor growth, and resistance to apoptosis, typically defining a biologically aggressive cancer subset that is selectively eligible for HER2-targeted oncologic therapies

This aberrant receptor overexpression drives unrestrained cellular proliferation, tumor growth, and resistance to apoptosis, typically defining a biologically aggressive cancer subset that is selectively eligible for HER2-targeted oncologic therapies